BioN­Tech to pay $200M up­front in CT­LA-4 an­ti­body de­vel­op­ment, com­mer­cial­iza­tion deal

BioN­Tech is branch­ing out in­to CT­LA-4 as part of a deal with the crew be­hind On­coIm­mune.

BioN­Tech and On­coC4 put out word Mon­day that they had reached an ex­clu­sive deal to co-de­vel­op and co-com­mer­cial­ize On­coC4’s mon­o­clon­al an­ti­body can­di­date for a va­ri­ety of can­cer in­di­ca­tions.

The deal will see BioN­Tech pay­ing On­coC4, a spin­out of On­coIm­mune, $200 mil­lion up­front for ONC-392, On­coC4’s an­ti-CT­LA-4 can­di­date — plus undis­closed mile­stone pay­ments and tiered roy­al­ties. On top of that, the com­pa­nies will joint­ly de­vel­op the drug and split de­vel­op­ment costs in sev­er­al sol­id tu­mor in­di­ca­tions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN